世界のコンタクトレンズ市場:医療機器パイプライン分析2016

◆英語タイトル:Contact Lenses - Medical Devices Pipeline Assessment, 2016
◆商品コード:GDME0169EPD
◆発行会社(調査会社):GlobalData
◆発行日:2016年4月1日
◆ページ数:172
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD4,000 ⇒換算¥456,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD8,000 ⇒換算¥912,000見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD12,000 ⇒換算¥1,368,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。



当調査レポートでは、コンタクトレンズのグローバル製品パイプライン動向について調査・分析し、以下の構成でお届けいたします。
・コンタクトレンズの概要
・コンタクトレンズの開発動向:開発段階別分析
・コンタクトレンズの開発動向:セグメント別分析
・コンタクトレンズの開発動向:領域別分析
・コンタクトレンズの開発動向:規制Path別分析
・コンタクトレンズの開発動向:承認日(推定)別分析
・企業別コンタクトレンズの開発動向(パイプライン製品、進行中の治験)
・コンタクトレンズの最近動向
【レポートの概要】

Contact Lenses – Medical Devices Pipeline Assessment, 2016

Summary

GlobalData’s Medical Devices sector report, “Contact Lenses – Medical Devices Pipeline Assessment, 2016″ provides an overview of Contact Lenses currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Contact Lenses pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData’s team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Contact Lenses under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Contact Lenses and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to –
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Contact Lenses under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date

【レポートの目次】

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 10
2 Introduction 11
2.1 Contact Lenses Overview 11
3 Products under Development 12
3.1 Contact Lenses – Pipeline Products by Stage of Development 12
3.2 Contact Lenses – Pipeline Products by Segment 13
3.3 Contact Lenses – Pipeline Products by Territory 14
3.4 Contact Lenses – Pipeline Products by Regulatory Path 15
3.5 Contact Lenses – Pipeline Products by Estimated Approval Date 16
3.6 Contact Lenses – Ongoing Clinical Trials 17
4 Contact Lenses – Pipeline Products under Development by Companies 18
4.1 Contact Lenses Companies – Pipeline Products by Stage of Development 18
4.2 Contact Lenses – Pipeline Products by Stage of Development 20
5 Contact Lenses Companies and Product Overview 23
5.1 Aeon Astron Corporation Company Overview 23
5.1.1 Aeon Astron Corporation Pipeline Products & Ongoing Clinical Trials Overview 23
5.2 Alcon, Inc. Company Overview 24
5.2.1 Alcon, Inc. Pipeline Products & Ongoing Clinical Trials Overview 24
5.3 Apeliotus Ophthalmics Company Overview 29
5.3.1 Apeliotus Ophthalmics Pipeline Products & Ongoing Clinical Trials Overview 29
5.4 Auburn University Company Overview 31
5.4.1 Auburn University Pipeline Products & Ongoing Clinical Trials Overview 31
5.5 Axcelon Biopolymers Corp. Company Overview 33
5.5.1 Axcelon Biopolymers Corp. Pipeline Products & Ongoing Clinical Trials Overview 33
5.6 Bausch & Lomb Incorporated Company Overview 34
5.6.1 Bausch & Lomb Incorporated Pipeline Products & Ongoing Clinical Trials Overview 34
5.7 Body Organ Biomedical Corp. Company Overview 38
5.7.1 Body Organ Biomedical Corp. Pipeline Products & Ongoing Clinical Trials Overview 38
5.8 Children’s Hospital Boston Company Overview 40
5.8.1 Children’s Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview 40
5.9 CooperVision, Inc. Company Overview 42
5.9.1 CooperVision, Inc. Pipeline Products & Ongoing Clinical Trials Overview 42
5.10 EP Global Communications, Inc. Company Overview 43
5.10.1 EP Global Communications, Inc. Pipeline Products & Ongoing Clinical Trials Overview 43
5.11 Euclid Systems Corporation Company Overview 44
5.11.1 Euclid Systems Corporation Pipeline Products & Ongoing Clinical Trials Overview 44
5.12 Eyenovations Company Overview 45
5.12.1 Eyenovations Pipeline Products & Ongoing Clinical Trials Overview 45
5.13 EyeYon Medical Company Overview 46
5.13.1 EyeYon Medical Pipeline Products & Ongoing Clinical Trials Overview 46
5.14 Imperial College London Company Overview 49
5.14.1 Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 49
5.15 Johnson & Johnson Vision Care, Inc. Company Overview 50
5.15.1 Johnson & Johnson Vision Care, Inc. Pipeline Products & Ongoing Clinical Trials Overview 50
5.16 Massachusetts Eye and Ear Infirmary Company Overview 54
5.16.1 Massachusetts Eye and Ear Infirmary Pipeline Products & Ongoing Clinical Trials Overview 54
5.17 Novartis AG Company Overview 56
5.17.1 Novartis AG Pipeline Products & Ongoing Clinical Trials Overview 56
5.18 Ocular Dynamics, LLC Company Overview 57
5.18.1 Ocular Dynamics, LLC Pipeline Products & Ongoing Clinical Trials Overview 57
5.19 Ocutec Limited Company Overview 58
5.19.1 Ocutec Limited Pipeline Products & Ongoing Clinical Trials Overview 58
5.20 Presbia Plc Company Overview 59
5.20.1 Presbia Plc Pipeline Products & Ongoing Clinical Trials Overview 59
5.21 Stanford University Company Overview 62
5.21.1 Stanford University Pipeline Products & Ongoing Clinical Trials Overview 62
5.22 The Hong Kong University of Science and Technology Company Overview 63
5.22.1 The Hong Kong University of Science and Technology Pipeline Products & Ongoing Clinical Trials Overview 63
5.23 The University of New South Wales Company Overview 64
5.23.1 The University of New South Wales Pipeline Products & Ongoing Clinical Trials Overview 64
5.24 UltraVision CLPL Company Overview 65
5.24.1 UltraVision CLPL Pipeline Products & Ongoing Clinical Trials Overview 65
5.25 University of California, San Diego Company Overview 66
5.25.1 University of California, San Diego Pipeline Products & Ongoing Clinical Trials Overview 66
5.26 University of Florida Company Overview 68
5.26.1 University of Florida Pipeline Products & Ongoing Clinical Trials Overview 68
5.27 University of Valencia Company Overview 69
5.27.1 University of Valencia Pipeline Products & Ongoing Clinical Trials Overview 69
5.28 University of Washington Company Overview 71
5.28.1 University of Washington Pipeline Products & Ongoing Clinical Trials Overview 71
5.29 University of Western Ontario Company Overview 74
5.29.1 University of Western Ontario Pipeline Products & Ongoing Clinical Trials Overview 74
5.30 Valeant Pharmaceuticals International, Inc. Company Overview 75
5.30.1 Valeant Pharmaceuticals International, Inc. Pipeline Products & Ongoing Clinical Trials Overview 75
5.31 Visioneering Technologies, Inc. Company Overview 95
5.31.1 Visioneering Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 95
5.32 VISTAKON Pharmaceuticals, LLC Company Overview 101
5.32.1 VISTAKON Pharmaceuticals, LLC Pipeline Products & Ongoing Clinical Trials Overview 101
5.33 Yolia Health Company Overview 102
5.33.1 Yolia Health Pipeline Products & Ongoing Clinical Trials Overview 102
6 Contact Lenses- Recent Developments 103
6.1 Mar 03, 2016: The Cooper Companies Announces First Quarter 2016 Results 103
6.2 Mar 01, 2016: First Patients in Presbia Microlens FDA Study Complete 12-Month Postoperative Visits 104
6.3 Feb 19, 2016: Strong growth in revenue and earnings Essilor focused on its 2018 objectives 104
6.4 Feb 12, 2016: Carl Zeiss Meditec Grows, Boosted by Currency Tailwinds / Strongest Growth Once Again in Surgical Ophthalmology 105
6.5 Feb 05, 2016: Briefing Summary of the Analyst/Investor Meeting for the 3rd Quarter Financial Results for the Fiscal Year Ending March 31, 2016 Tokyo, January 29, 2016 106
6.6 Jan 29, 2016: Hoya Reports Third Quarter Results; Record Nine Months Results 109
6.7 Jan 27, 2016: Novartis delivered strong sales growth and core margin expansion (cc[1]) in 2015; announces plans to accelerate growth at Alcon, streamline Group operations 110
6.8 Jan 15, 2016: HOYA Presents Hoya EyeGenius 119
6.9 Dec 16, 2015: AEA Investors to Acquire Majority Stake in 1-800 Contacts from Thomas H. Lee Partners 120
6.10 Dec 16, 2015: Carl Zeiss Meditec increases revenue to € 1,040 million / Market shares expanded in a number of markets 120
6.11 Dec 03, 2015: The Cooper Companies Announces Fourth Quarter and Full Year 2015 Results 121
6.12 Nov 10, 2015: Bausch + Lomb Announces 2016 Launch of Bausch + Lomb ULTRA Contact Lenses for Presbyopia 122
6.13 Nov 09, 2015: Unicon Optical to Acquire Taiwan-Based Contact Lenses Company 123
6.14 Nov 06, 2015: Shanghai Conant Optics Plans to Raise up to USD188.6 Million in Private Placement of Shares 123
6.15 Oct 27, 2015: Novartis delivered strong core margin expansion (cc) and continued to strengthen the pipeline in Q3; on track for full-year guidance 123
6.16 Oct 26, 2015: Valeant Pharma Receives FTC Voluntary Request Letter Related To Paragon Holdings Acquisition 130
6.17 Oct 12, 2015: EPGL to Grant CooperVision Exclusive Licenses in Exchange for Royalties and Compensation Agreement by November 6, 2015 131
6.18 Oct 08, 2015: Robins Kaplan LLP Named Co-Lead Counsel in Disposable Contact Lens Antitrust Litigation 131
6.19 Oct 05, 2015: Presbia Introduces Time-Saving Disposable Microlens Inserter 132
6.20 Sep 17, 2015: Presbia Flexivue Microlens Implanted in More Than 1,000 Patients Worldwide 132
6.21 Sep 17, 2015: QSpex Technologies Enters into Agreement with Shanghai Conant Optical 132
6.22 Sep 14, 2015: HOYA Vision Care Establishes Subsidiary in Turkey 133
6.23 Sep 10, 2015: Presbia Completes Second Stage Enrollment in the US FDA Pivotal Study of Presbia Flexivue Microlens 133
6.24 Sep 10, 2015: Johnson & Johnson Vison Care Launches New Lens With A Tear-Infused Design 133
6.25 Sep 03, 2015: Presbia to Complete Second Stage Enrollment in the US FDA Pivotal Study of Presbia Flexivue Microlens 134
6.26 Sep 03, 2015: The Cooper Companies Announces Third Quarter 2015 Results 135
6.27 Aug 24, 2015: Results of Patient Outcomes Outside of the U.S. Demonstrate Safety and Effectiveness of Presbia Flexivue Mircolens 136
6.28 Aug 10, 2015: Presbia Surpasses Treatment of 300 Subjects as Part of the US FDA Pivotal Study Enrollment 136
6.29 Aug 05, 2015: Essilor International Raises USD328.4 Million in Public Offering of Notes Due 2017 137
6.30 Aug 03, 2015: Xavier Galliot, Chief Sustainability Officer of the Essilor Group 137
6.31 Jul 30, 2015: Essilor of America to Acquire Vision Source from Brazos Private Equity 137
6.32 Jul 30, 2015: Essilor Announces Strong results ; A winning strategy 137
6.33 Jul 29, 2015: Hoya Announces First Quarter Results Ended June 30, 2015 138
6.34 Jul 29, 2015: Hoya Reports First Quarter Financial Results 140
6.35 Jul 28, 2015: Valeant Pharmaceuticals Presented with Economic Development Support from Rochester Gas & Electric for the Bausch + Lomb ULTRA Contact Lens Manufacturing Line Expansion in Rochester, NY 141
6.36 Jul 21, 2015: Novartis delivered solid performance in the second quarter, with strong innovation and progress on new launches 141
6.37 Jul 13, 2015: Valeant Pharma to Acquire Unilens Vision 149
6.38 Jul 09, 2015: Presbia Reaches the Halfway Mark in Second Stage Enrollment in the US FDA Pivotal Study 149
6.39 Jun 23, 2015: Bausch + Lomb’s Biotrue ONEday for Presbyopia Contact Lenses Now Available in Expanded High Add Powers 149
6.40 Jun 22, 2015: Visioneering Technologies Taps MidSouth Premier Ophthalmics as Exclusive Distributor for NaturalVue Lenses 150
6.41 Jun 04, 2015: The Cooper Companies Announces Second Quarter 2015 Results 150
6.42 Jun 01, 2015: NVISION Eye Centers Performs First KAMRA Inlay in California 151
6.43 May 15, 2015: Ultravision Expands Licensing Agreement with Art Optical 152
6.44 May 14, 2015: Unilens Vision Reports Third Quarter Operating Results 152
6.45 May 12, 2015: Hoya Reports Fourth Quarter Results; Achieves Record Annual Sales and Profit 154
6.46 May 04, 2015: NVISION Eye Centers Becomes One of the First in the U.S. to Offer Breakthrough KAMRA Inlay for Near Vision Loss Associated With Aging 155
6.47 May 03, 2015: Bausch + Lomb Presents New Scientific and Clinical Research During the Association for Research in Vision and Ophthalmology Annual Meeting in Denver, CO 155
6.48 Apr 23, 2015: Novartis delivered sales growth, significant margin expansion and strong innovation in Q1; now with a more focused portfolio 156
6.49 Apr 21, 2015: Presbia Announces the Start of Commercialization of the Presbia Flexivue Micolens in Australia 163
6.50 Apr 21, 2015: Revenue up very sharply by 25.4% Annual targets confirmed 163
6.51 Apr 18, 2015: Durrie Vision First in Region to Provide Corneal Implant Designed to Treat Presbyopia 165
6.52 Apr 18, 2015: ZEISS Showcases Integrated Solutions that Deliver Faster Practice and Surgical Workflow and Address Critical Diagnostic Challenges 165
6.53 Apr 17, 2015: FDA approves first-of-its-kind corneal implant to improve near vision in certain patients 167
6.54 Apr 16, 2015: Visioneering Technologies Introduces NaturalVue 1 Day Multifocal Contact Lens Works with the Brain to Optimize Vision 168
7 Appendix 169
7.1 Methodology 169
7.2 About GlobalData 171
7.3 Contact Us 172
7.4 Disclaimer 172

1.1 List of Tables
Table 1: Contact Lenses - Pipeline Products by Stage of Development 12
Table 2: Contact Lenses - Pipeline Products by Segment 13
Table 3: Contact Lenses - Pipeline Products by Territory 14
Table 4: Contact Lenses - Pipeline Products by Regulatory Path 15
Table 5: Contact Lenses - Pipeline Products by Estimated Approval Date 16
Table 6: Contact Lenses - Ongoing Clinical Trials 17
Table 7: Contact Lenses Companies - Pipeline Products by Stage of Development 18
Table 8: Contact Lenses - Pipeline Products by Stage of Development 20
Table 9: Aeon Astron Corporation Pipeline Products & Ongoing Clinical Trials Overview 23
Table 10: Body Organ Contact Lens - Product Status 23
Table 11: Body Organ Contact Lens - Product Description 23
Table 12: Alcon, Inc. Pipeline Products & Ongoing Clinical Trials Overview 24
Table 13: Dailies Total 1 Colors SiHy Lens - Product Status 24
Table 14: Dailies Total 1 Colors SiHy Lens - Product Description 24
Table 15: Dailies Total 1 Multifocal SiHy Lens - Product Status 25
Table 16: Dailies Total 1 Multifocal SiHy Lens - Product Description 25
Table 17: Dailies Total 1 Toric SiHy Lens - Product Status 26
Table 18: Dailies Total 1 Toric SiHy Lens - Product Description 26
Table 19: Smart Lens - Diabetes - Product Status 27
Table 20: Smart Lens - Diabetes - Product Description 27
Table 21: Weekly WG SiHy Lens - Product Status 28
Table 22: Weekly WG SiHy Lens - Product Description 28
Table 23: Apeliotus Ophthalmics Pipeline Products & Ongoing Clinical Trials Overview 29
Table 24: Comfort Lens - Product Status 29
Table 25: Comfort Lens - Product Description 29
Table 26: Contact Lens - Glaucoma - Product Status 30
Table 27: Contact Lens - Glaucoma - Product Description 30
Table 28: Auburn University Pipeline Products & Ongoing Clinical Trials Overview 31
Table 29: Smart Contact Lenses - Product Status 32
Table 30: Smart Contact Lenses - Product Description 32
Table 31: Axcelon Biopolymers Corp. Pipeline Products & Ongoing Clinical Trials Overview 33
Table 32: MC - PHEMA Based Contact Lens - Product Status 33
Table 33: MC - PHEMA Based Contact Lens - Product Description 33
Table 34: Bausch & Lomb Incorporated Pipeline Products & Ongoing Clinical Trials Overview 34
Table 35: Ultra Multi Focal Lens - Product Status 35
Table 36: Ultra Multi Focal Lens - Product Description 35
Table 37: Ultra Plus Powers Lens - Product Status 36
Table 38: Ultra Plus Powers Lens - Product Description 36
Table 39: Ultra Toric Lens - Product Status 37
Table 40: Ultra Toric Lens - Product Description 37
Table 41: Body Organ Biomedical Corp. Pipeline Products & Ongoing Clinical Trials Overview 38
Table 42: Biolens - Product Status 39
Table 43: Biolens - Product Description 39
Table 44: Children's Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview 40
Table 45: Contact Lens Drug Delivery Device - Product Status 41
Table 46: Contact Lens Drug Delivery Device - Product Description 41
Table 47: CooperVision, Inc. Pipeline Products & Ongoing Clinical Trials Overview 42
Table 48: SiH Multifocal - Product Status 42
Table 49: SiH Multifocal - Product Description 42
Table 50: EP Global Communications, Inc. Pipeline Products & Ongoing Clinical Trials Overview 43
Table 51: EP Global Contact Lens - Product Status 43
Table 52: EP Global Contact Lens - Product Description 43
Table 53: Euclid Systems Corporation Pipeline Products & Ongoing Clinical Trials Overview 44
Table 54: Drug-Eluting Contact Lenses - Product Status 44
Table 55: Drug-Eluting Contact Lenses - Product Description 44
Table 56: Eyenovations Pipeline Products & Ongoing Clinical Trials Overview 45
Table 57: Drug Dispensing Contact Lens - Product Status 45
Table 58: Drug Dispensing Contact Lens - Product Description 45
Table 59: EyeYon Medical Pipeline Products & Ongoing Clinical Trials Overview 46
Table 60: Hyper-CL - Product Status 46
Table 61: Hyper-CL - Product Description 46
Table 62: EyeYon Medical - Ongoing Clinical Trials Overview 47
Table 63: Hyper-CL - Prospective, Randomized Crossover Study of Using the Hyper-CL Lens (Hyper Osmotic Contact Lens) in Subjects Suffering from Corneal Edema 48
Table 64: Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 49
Table 65: Contact Lens - Product Status 49
Table 66: Contact Lens - Product Description 49
Table 67: Johnson & Johnson Vision Care, Inc. Pipeline Products & Ongoing Clinical Trials Overview 50
Table 68: 1-DAY ACUVUE Multifocal Contact Lens - Product Status 51
Table 69: 1-DAY ACUVUE Multifocal Contact Lens - Product Description 51
Table 70: Anti-allergic Contact Lens - Product Status 52
Table 71: Anti-allergic Contact Lens - Product Description 52
Table 72: Next Generation 1-DAY ACUVUE DEFINE Contact Lens - Product Status 53
Table 73: Next Generation 1-DAY ACUVUE DEFINE Contact Lens - Product Description 53
Table 74: Massachusetts Eye and Ear Infirmary Pipeline Products & Ongoing Clinical Trials Overview 54
Table 75: Therapeutic Contact Lens - Product Status 55
Table 76: Therapeutic Contact Lens - Product Description 55
Table 77: Novartis AG Pipeline Products & Ongoing Clinical Trials Overview 56
Table 78: CLM041 - Product Status 56
Table 79: CLM041 - Product Description 56
Table 80: Ocular Dynamics, LLC Pipeline Products & Ongoing Clinical Trials Overview 57
Table 81: Contact Lens - Dry Eye Disease - Product Status 57
Table 82: Contact Lens - Dry Eye Disease - Product Description 57
Table 83: Ocutec Limited Pipeline Products & Ongoing Clinical Trials Overview 58
Table 84: Third PEG Hydrogel Contact Lens - Product Status 58
Table 85: Third PEG Hydrogel Contact Lens - Product Description 58
Table 86: Presbia Plc Pipeline Products & Ongoing Clinical Trials Overview 59
Table 87: Flexivue Microlens - Product Status 59
Table 88: Flexivue Microlens - Product Description 59
Table 89: Presbia Plc - Ongoing Clinical Trials Overview 60
Table 90: Flexivue Microlens - A Phase II trial of Presbia Flexivue Microlens for The Treatment of Presbyopia 61
Table 91: Flexivue Microlens - Prospective, Non-randomized, Unmasked, Multicenter Clinical Investigation of the Presbia Flexivue Microlens for the Improvement of Near Vision in Emmetropic Presbyopes 61
Table 92: Stanford University Pipeline Products & Ongoing Clinical Trials Overview 62
Table 93: Polymer Network Hydrogel Contact Lens - Product Status 62
Table 94: Polymer Network Hydrogel Contact Lens - Product Description 62
Table 95: The Hong Kong University of Science and Technology Pipeline Products & Ongoing Clinical Trials Overview 63
Table 96: Resonance Circuit Sensor Contact Lens - Product Status 63
Table 97: Resonance Circuit Sensor Contact Lens - Product Description 63
Table 98: The University of New South Wales Pipeline Products & Ongoing Clinical Trials Overview 64
Table 99: Stem Cell Contact Lens - Product Status 64
Table 100: Stem Cell Contact Lens - Product Description 64
Table 101: UltraVision CLPL Pipeline Products & Ongoing Clinical Trials Overview 65
Table 102: Contact Lenses - Product Status 65
Table 103: Contact Lenses - Product Description 65
Table 104: University of California, San Diego Pipeline Products & Ongoing Clinical Trials Overview 66
Table 105: Aerated Contact Lens - Product Status 66
Table 106: Aerated Contact Lens - Product Description 66
Table 107: Telescopic Contact Lens - Product Status 67
Table 108: Telescopic Contact Lens - Product Description 67
Table 109: University of Florida Pipeline Products & Ongoing Clinical Trials Overview 68
Table 110: Vitamin E - Packed Lenses - Product Status 68
Table 111: Vitamin E - Packed Lenses - Product Description 68
Table 112: University of Valencia Pipeline Products & Ongoing Clinical Trials Overview 69
Table 113: Multifocal Contact Lens - Myopia - Product Status 69
Table 114: Multifocal Contact Lens - Myopia - Product Description 69
Table 115: Multifocal Contact Lens - Presbyopia - Product Status 70
Table 116: Multifocal Contact Lens - Presbyopia - Product Description 70
Table 117: University of Washington Pipeline Products & Ongoing Clinical Trials Overview 71
Table 118: Bionic Contact Lens - Product Status 72
Table 119: Bionic Contact Lens - Product Description 72
Table 120: Solar Powered Augmented Lenses - Product Status 73
Table 121: Solar Powered Augmented Lenses - Product Description 73
Table 122: University of Western Ontario Pipeline Products & Ongoing Clinical Trials Overview 74
Table 123: Nanocomposite Hydrogel Lenses - Product Status 74
Table 124: Nanocomposite Hydrogel Lenses - Product Description 74
Table 125: Valeant Pharmaceuticals International, Inc. Pipeline Products & Ongoing Clinical Trials Overview 75
Table 126: BLC - 001: SVS - Product Status 76
Table 127: BLC - 001: SVS - Product Description 76
Table 128: BLC - 002: SVS - Product Status 77
Table 129: BLC - 002: SVS - Product Description 77
Table 130: BLC - 003: SVS/MF/fA - Product Status 78
Table 131: BLC - 003: SVS/MF/fA - Product Description 78
Table 132: BLC - 004: Toric - Product Status 79
Table 133: BLC - 004: Toric - Product Description 79
Table 134: BLC - 005: SVS/MF - Product Status 80
Table 135: BLC - 005: SVS/MF - Product Description 80
Table 136: BLC - 006: SVS - Product Status 81
Table 137: BLC - 006: SVS - Product Description 81
Table 138: BLC - 007: MF - Product Status 82
Table 139: BLC - 007: MF - Product Description 82
Table 140: BLC - 008: Astigmatism - Product Status 83
Table 141: BLC - 008: Astigmatism - Product Description 83
Table 142: BLC - 009: Astigmatism - Product Status 84
Table 143: BLC - 009: Astigmatism - Product Description 84
Table 144: XUV - 003: Aphakia - Product Status 85
Table 145: XUV - 003: Aphakia - Product Description 85
Table 146: XUV - 004: SVS - Product Status 86
Table 147: XUV - 004: SVS - Product Description 86
Table 148: XUV - 007: MF - Product Status 87
Table 149: XUV - 007: MF - Product Description 87
Table 150: XUV - 009: SVS - Product Status 88
Table 151: XUV - 009: SVS - Product Description 88
Table 152: XUV - 010: Astigmatism - Product Status 89
Table 153: XUV - 010: Astigmatism - Product Description 89
Table 154: XUV - 011: MF - Product Status 90
Table 155: XUV - 011: MF - Product Description 90
Table 156: XUV - 012: SVS - Product Status 91
Table 157: XUV - 012: SVS - Product Description 91
Table 158: XUV - 013: SVS - Product Status 92
Table 159: XUV - 013: SVS - Product Description 92
Table 160: XUV - 014: Presbyopia - Product Status 93
Table 161: XUV - 014: Presbyopia - Product Description 93
Table 162: XUV - 015: MF - Product Status 94
Table 163: XUV - 015: MF - Product Description 94
Table 164: Visioneering Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 95
Table 165: Contact Lens - Product Status 96
Table 166: Contact Lens - Product Description 96
Table 167: NaturalVue Sphere 1 Day Contact Lenses - Product Status 97
Table 168: NaturalVue Sphere 1 Day Contact Lenses - Product Description 97
Table 169: NaturalVue Toric 1 Day Contact Lenses - Product Status 98
Table 170: NaturalVue Toric 1 Day Contact Lenses - Product Description 98
Table 171: NaturalVue Toric Multifocal 1 Day Contact Lenses - Product Status 99
Table 172: NaturalVue Toric Multifocal 1 Day Contact Lenses - Product Description 99
Table 173: VTI MPC Lens - Product Status 100
Table 174: VTI MPC Lens - Product Description 100
Table 175: VISTAKON Pharmaceuticals, LLC Pipeline Products & Ongoing Clinical Trials Overview 101
Table 176: K-Lens - Product Status 101
Table 177: K-Lens - Product Description 101
Table 178: Yolia Health Pipeline Products & Ongoing Clinical Trials Overview 102
Table 179: TVT Device - Product Status 102
Table 180: TVT Device - Product Description 102
Table 181: Glossary 170

1.2 List of Figures
Figure 1: Contact Lenses - Pipeline Products by Stage of Development 12
Figure 2: Contact Lenses - Pipeline Products by Segment 13
Figure 3: Contact Lenses - Pipeline Products by Territory 14
Figure 4: Contact Lenses - Pipeline Products by Regulatory Path 15
Figure 5: Contact Lenses - Pipeline Products by Estimated Approval Date 16
Figure 6: Contact Lenses - Ongoing Clinical Trials 17

【掲載企業】

Aeon Astron Corporation
Alcon, Inc.
Apeliotus Ophthalmics
Auburn University
Axcelon Biopolymers Corp.
Bausch & Lomb Incorporated
Body Organ Biomedical Corp.
Children's Hospital Boston
CooperVision, Inc.
EP Global Communications, Inc.
Euclid Systems Corporation
Eyenovations
EyeYon Medical
Imperial College London
Johnson & Johnson Vision Care, Inc.
Massachusetts Eye and Ear Infirmary
Novartis AG
Ocular Dynamics, LLC
Ocutec Limited
Presbia Plc
Stanford University
The Hong Kong University of Science and Technology
The University of New South Wales
UltraVision CLPL
University of California, San Diego
University of Florida
University of Valencia
University of Washington
University of Western Ontario
Valeant Pharmaceuticals International, Inc.
Visioneering Technologies, Inc.
VISTAKON Pharmaceuticals, LLC
Yolia Health

【レポートのキーワード】

コンタクトレンズ

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[世界のコンタクトレンズ市場:医療機器パイプライン分析2016]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。
※当サイトでは2016年12月11日現在 219,328 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆